TABLE 2.
Adherence Comparison Between Rivaroxaban, Dabigatran, and Apixaban Users at 3, 6, and 9 Months of Follow-up
| 3 Months | ||||
|---|---|---|---|---|
| Rivaroxaban n=9,817 | Dabigatran n=2,751 | Apixaban n=2,773 | P Value | |
| PDCa | ||||
| Mean (SD) | 0.83 (0.26) | 0.76 (0.29) | 0.82 (0.26) | < 0.001 |
| ≥ 0.80, n (%) | 6,974 (71.0) | 1,663 (60.5) | 1,974 (71.2) | < 0.001 |
| 0.50-0.79, n (%) | 1,201 (12.2) | 421 (15.3) | 383 (13.8) | |
| < 0.50, n (%) | 1,642 (16.7) | 667 (24.3) | 416 (15.0) | |
| Gaps,b n (%) | ||||
| ≥ 15 days | 877 (8.9) | 331 (12.0) | 334 (12.0) | < 0.001 |
| ≥ 30 days | 326 (3.3) | 127 (4.6) | 127 (4.6) | 0.018 |
| ≥ 60 days | 57 (0.6) | 24 (0.9) | 22 (0.8) | 0.174 |
| Switch,c n (%) | ||||
| Other OAC | 571 (5.8) | 336 (12.2) | 187 (6.8) | < 0.001 |
| Antiplatelet | 199 (2.0) | 63 (2.3) | 50 (1.8) | 0.438 |
| 6 Months | ||||
| Rivaroxaban n = 8,908 | Dabigatran n = 2,607 | Apixaban n = 2,329 | P Value | |
| PDCa | ||||
| Mean (SD) | 0.73 (0.32) | 0.64 (0.34) | 0.72 (0.31) | < 0.001 |
| ≥ 0.80, n (%) | 5,300 (59.5) | 1,245 (47.8) | 1,398 (60.0) | < 0.001 |
| 0.50-0.79, n (%) | 1,569 (17.6) | 524 (20.1) | 454 (19.5) | |
| < 0.50, n (%) | 2,039 (22.9) | 838 (32.1) | 477 (20.5) | |
| Gaps,b n (%) | ||||
| ≥ 15 days | 1,538 (17.1) | 612 (23.5) | 550 (23.4) | < 0.001 |
| ≥ 30 days | 790 (8.8) | 319 (12.2) | 293 (12.5) | < 0.001 |
| ≥ 60 days | 276 (3.1) | 118 (4.5) | 95 (4.1) | 0.022 |
| Switch,c n (%) | ||||
| Other OAC | 735 (8.2) | 445 (17.1) | 214 (9.1) | < 0.001 |
| Antiplatelet | 261 (2.9) | 100 (3.8) | 69 (2.9) | 0.044 |
| 9 Months | ||||
| Rivaroxaban n=7,969 | Dabigatran n=2,456 | Apixaban n=1,858 | P Value | |
| PDCa | ||||
| Mean (SD) | 0.66 (0.34) | 0.57 (0.35) | 0.66 (0.33) | < 0.001 |
| ≥ 0.80, n (%) | 3,753 (47.1) | 912 (37.1) | 889 (47.9) | < 0.001 |
| 0.50-0.79, n (%) | 1,421 (17.8) | 432 (17.6) | 356 (19.2) | |
| < 0.50, n (%) | 2,795 (35.1) | 1,112 (45.3) | 613 (33.0) | |
| Gaps,b n (%) | ||||
| ≥ 15 days | 1,578 (20.8) | 591 (25.3) | 482 (27.3) | < 0.001 |
| ≥ 30 days | 902 (11.9) | 335 (14.3) | 280 (15.9) | < 0.001 |
| ≥ 60 days | 408 (5.4) | 158 (6.8) | 111 (6.3) | 0.052 |
| Switch,c n (%) | ||||
| Other OAC | 719 (9.5) | 440 (18.8) | 185 (10.5) | < 0.001 |
| Antiplatelet | 256 (3.4) | 90 (3.9) | 60 (3.4) | 0.538 |
aPDC = sum of days supply from initiation of therapy to the end of the time period divided by time period length (90, 180, or 270 days). Prescription fills were corrected for early refills and credited to the numerator.
bGaps were any period where no treatments (OAC or antiplatelet) were observed. Gap lengths (15, 30, 60 days) were not mutually exclusive.
cIndividuals with a switch or a gap who reinitiated the index medication after the gap or switch and within the time period.
OAC = oral anticoagulant; PDC = proportion of days covered; SD = standard deviation.